BICYCLE THERAPEUTICS PLC

CAMBRIDGE, X0 · CIK 0001761612 · Biotech · Public

Bicyclic peptide therapeutics for solid tumors

bicycletherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$555M
1 Form D · Jun 2024
28 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$555,499,983
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2303Relay Therapeutics—$30M
2304Acurx Pharmaceuticals, Inc.—$17M
2305Congruence Therapeutics——
2306BICYCLE THERAPEUTICS PLC—$555M
2307Gatehouse Bio, Inc.—$5.4M
2308Synlico Inc.—$5.2M
2309Humonix Biosciences Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • SANTIAGO ARROYOExecutive Officer
  • FELIX BAKERDirector
  • JANICE BOURQUEDirector
  • NIGEL CROCKETTExecutive Officer
  • JOSE-CARLOS GUTIERREZ-RAMOSDirector
  • MICHAEL HANNAYExecutive Officer
  • NICHOLAS KEENExecutive Officer
  • RICHARD KENDERDirector
  • KEVIN LEEDirector · Executive Officer
  • PIERRE LEGAULTDirector
  • ALISTAIR MILNESExecutive Officer
  • STEPHEN SANDSDirector
  • MICHAEL SKYNNERExecutive Officer
  • GREGORY WINTERDirector
  • ALETHIA YOUNGExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.